B
REGN icon

Bellecapital’s Regeneron Pharmaceuticals REGN Stock Holding History

Bellecapital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Buy
27,594
+3,308
+14% +$2.25M 2.75% 16
2026
Q1 		$18.8M Buy
24,286
+1,177
+5% +$901K 3.39% 8
2025
Q4 		$17.8M Sell
23,109
-4,670
-17% -$3.17M 3.17% 9
2025
Q3 		$15.6M Buy
27,779
+2,276
+9% +$1.29M 2.52% 15
2025
Q2 		$13.4M Buy
25,503
+6,283
+33% +$3.51M 2.38% 16
2025
Q1 		$12.2M Sell
19,220
-380
-2% -$261K 2.41% 16
2024
Q4 		$14M Buy
19,600
+6,002
+44% +$5.04M 2.47% 15
2024
Q3 		$14.3M Buy
13,598
+226
+2% +$252K 2.84% 12
2024
Q2 		$14.1M Buy
13,372
+192
+1% +$186K 2.98% 11
2024
Q1 		$12.7M Buy
13,180
+158
+1% +$150K 2.8% 11
2023
Q4 		$11.4M Buy
13,022
+502
+4% +$413K 2.59% 12
2023
Q3 		$10.3M Buy
12,520
+151
+1% +$119K 2.58% 9
2023
Q2 		$8.89M Sell
12,369
-4
-0% -$3.08K 2.15% 13
2023
Q1 		$10.2M Buy
12,373
+206
+2% +$155K 2.53% 8
2022
Q4 		$8.78M Buy
12,167
+168
+1% +$124K 2.47% 12
2022
Q3 		$8.27M Buy
11,999
+2,648
+28% +$1.67M 2.52% 11
2022
Q2 		$5.53M Buy
+9,351
New +$6.08M 1.54% 18

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bellecapital's REGN Position: Q2 2026 in Review

Bellecapital increased its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, buying an estimated $2.25M and bringing the position to 27,594 shares worth $17.2M. The position accounts for 2.75% of the portfolio, ranked #16.

Bellecapital first reported a position in REGN in Q2 2022 and has held it in 17 quarters since. The position peaked at $18.8M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bellecapital held 27,594 shares of Regeneron Pharmaceuticals worth $17.2M as of Q2 2026.
  • Bellecapital bought 3,308 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • Regeneron Pharmaceuticals made up 2.75% of Bellecapital's portfolio in Q2 2026, its #16 holding.
  • Bellecapital first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Bellecapital's Regeneron Pharmaceuticals position peaked at $18.8M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bellecapital's 13F filing for Q2 2026, filed 22 Jul 2026.